Continued versus discontinued oral anticoagulant treatment for unprovoked venous thromboembolism: target trial emulation
Based on two US nationally representative routine care databases, continuing versus discontinuing OAC after initial anticoagulation of ≥90 days was associated with lower risk of recurrent VTE, higher risk of major bleeding, and a net clinical benefit. This observation persisted among those using OACs for at least three years after VTE.
Authors
- Anthony Kehoe (ORCID: https://orcid.org/0000-0002-2083-645X)
- Kueiyu Joshua Lin (ORCID: https://orcid.org/0000-0003-4564-3715)
- Alexander Cervone
- Katsiaryna Bykov (ORCID: https://orcid.org/0000-0003-3336-5412)
- Dae‐Hyun Kim (ORCID: https://orcid.org/0000-0002-3525-3812)
- Yichi Zhang (ORCID: https://orcid.org/0000-0003-4885-9028)
- Daniel E. Singer
Institutions
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Hebrew SeniorLife (US)
Publication Details
- Journal
- BMJ
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1136/bmj-2025-084380
- Citations
- 2
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.74
Funders
- Massachusetts General Hospital
- Patient-Centered Outcomes Research Institute